A study from Tassorelli's group demonstrated that patients with anxiety disorders are less likely to respond to anti‐CGRP mAbs (Bottiroli et al., 2021), confirming the results obtained in another study among CM sufferers treated with galcanezumab in 2020 (Smitherman et al., 2020). Here, CALCA is linked to anxiety disorder.